Azitra adds MD Anderson Cancer Center as site for Phase 1/2 skin rash trial

Azitra (AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04. ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor-associated rash. The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinical study is designed to evaluate the safety and tolerability of topical ATR04-484 for the treatment of EGFRi-associated dermal toxicity affecting the face of adult patients. The key objectives of the study will be to assess the safety and tolerability of topical ATR04-484 and to evaluate early efficacy signals. The study is currently enrolling patients for Cohort 1, which is anticipated to enroll a total of eight patients.